Latest Cypher stent Stories

2015-02-04 08:29:35

-- Novel Drug-delivery Technology Provides Sirolimus-Eluting Stent with Unique Bioabsorbable Polymer Absorption and Drug Release Profile -- DURHAM, N.C., Feb.

2014-06-09 23:06:19

Transparency Market Research added a new report "Drug Eluting Balloons Market: Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2013 - 2019" to its report store.

2011-06-15 08:00:00

BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO(TM) Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists.

2010-09-30 02:58:00

WATERLOO, Belgium, September 30, 2010 /PRNewswire/ -- - SORT OUT IV Data Presented at TCT in Washington DC Shows Remarkable Clinical Safety and Efficacy Measures With Both CYPHER(R) Stent and XIENCE V(R) Stent - Only CYPHER Stent has More Than 10 years of Clinical Safety Data in 70 Studies Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent and Abbott's XIENCE V (R) Everolimus-eluting Stent in the primary...

2010-09-02 06:59:00

STOCKHOLM, September 2, 2010 /PRNewswire/ -- - Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions Three new analyses of subgroups from the SORT OUT III study presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden, provide additional detail on longer-term follow-up subgroup safety and efficacy outcomes in the SORT...

2010-08-31 05:20:00

STOCKHOLM, August 31, 2010 /PRNewswire/ -- - The Publication of 10-Year Follow-Up Test Results on the First CYPHER(R) Sirolimus-Eluting Coronary Stent Patient Reveal the Stent's Outstanding Efficacy and Safety Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a...

2010-02-01 07:00:00

BRIDGEWATER, N.J., Feb. 1 /PRNewswire/ -- Cordis Corporation, a Johnson & Johnson company, announced today that it has reached an agreement with Boston Scientific resolving two Delaware litigations related to Cordis's Palmaz and Gray patents and Boston Scientific's Jang patents.

2009-05-11 07:30:00

Authors identify important differences between drug-eluting stent brands NATICK, Mass., May 11 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an article in the current edition of the Journal of American College of Cardiology (JACC) reviewing data on more than 19,000 patients from the Swedish national registry who were evaluated for restenosis, or the re-narrowing of arteries after percutaneous coronary intervention (PCI).

2009-01-15 12:23:00

WARREN, N.J., Jan. 15 /PRNewswire/ -- The Court of Appeals for the Federal Circuit in Washington, D.C. today found Boston Scientific Corporation's Ding patent invalid, and reversed a 2005 jury finding that Cordis Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent infringed that patent.

Word of the Day
  • A serpent whose bite was fabled to produce intense thirst.
The word 'dipsas' comes from a Greek word meaning 'thirst'.